On December 6, Guolonghui | CMB International issued a research report pointing out that due to the continuous support of medical insurance funds for innovative drugs, it is expected that the prices of renewed varieties of 3sbio will remain stable, providing support for its steady growth. At the same time, benefiting from the expansion of indications and improved penetration rate, it is expected that its drug Tibsovo will continue to grow rapidly in the 2025 fiscal year. CMB International also pointed out that the pipeline progress of 3sbio's innovative drugs is proceeding smoothly, with multiple innovative varieties already entering the NDA or Phase III clinical trials, thus expecting new products to gradually become an important growth engine for the company starting from 2026. In addition, CMB International expects that the revenue of 3sbio in the fiscal years 2024 and 2025 will grow by 12.8% and 12.2% respectively, expecting the company to maintain a 30% dividend payout ratio, therefore slightly raising its target price to HKD 9.81 and giving it a "buy" rating.